Can Tremfya turn radiographic evidence into a commercial advantage for Johnson & Johnson?
Find out how Johnson & Johnson’s Tremfya label expansion could reshape IL-23 competition in psoriatic arthritis care.
Pharma & Biotech
Pharma & Biotech
Johnson & Johnson’s three-year TREMFYA data sharpen the durability debate in ulcerative colitis care
Johnson & Johnson’s three-year TREMFYA data highlight why sustained remission is redefining ulcerative colitis treatment decisions. Read the analysis.